IOGERONTOLOGY AND TRANSLATIONAL EDICINE CAN WE … · 29 - 2 dicembre INVECCHIAMENTO: SCENARIO 2 0...
35
BIOGERONTOLOGY AND TRANSLATIONAL MEDICINE: HOW CAN WE REACH “OPTIMAL L ONGEVITY”? Emanuele Marzetti, MD, PhD Dept. of Geriatrics, Neurosciences and Orthopedics Center for Geriatric Medicine (Ce.M.I.) Teaching Hospital “Agostino Gemelli” Rome - Italy Napoli, 30 novembre 2017
Transcript of IOGERONTOLOGY AND TRANSLATIONAL EDICINE CAN WE … · 29 - 2 dicembre INVECCHIAMENTO: SCENARIO 2 0...
BIOGERONTOLOGY AND TRANSLATIONAL MEDICINE: HOW CAN WE REACH “OPTIMAL LONGEVITY”?
Emanuele Marzetti, MD, PhD
Dept. of Geriatrics, Neurosciences and Orthopedics Center for Geriatric Medicine (Ce.M.I.) Teaching Hospital “Agostino Gemelli”
Rome - Italy
Napoli, 30 novembre 2017
• Consultant for Novartis
• Consultant for Huron Consulting Group
• Consultant for Genactis
• Consultant for Nutricia
• Academic Leader of Work-Package 8 (analysis of results) of the SPRINTT Project (IMI–JU 115621)
CONFLICT OF INTEREST DISCLOSURE
NO END TO BAD NEWS…
• Which side effects? • Since senescence occurs differently across tissues and cell
types, how many drugs should one be taking? • To prove that senolytics prevent people from aging, enough
time needs to pass to show that they have not.
Laron syndrome: insensitivity to GH, very short stature, frequent obesity and dyslipidemia, reduced incidence of cancer and type II diabetes.
Roy Lee Walford
HARA HACHI BU
Targeting/Taming Aging With Metformin: the TAME study
Prof. Roberto Bernabei Prof. Francesco Landi Prof. Giulio Maccauro Dr. Riccardo Calvani Dr. Anna Picca Dr. Matteo Tosato
FUNDING Innovative Medicines Initiative – Joint Undertaking (IMI–JU 115621) Italian Ministry of Education and Research (D3.2 2013 and D3.2 2015) Achille and Linda Lorenzon Study Centre Fondazione Roma (NCDs call for proposals 2013)
